Tonix Pharmaceuticals Holding (TNXP) Income from Continuing Operations: 2017-2024
Historic Income from Continuing Operations for Tonix Pharmaceuticals Holding (TNXP) over the last 8 years, with Dec 2024 value amounting to -$136.7 million.
- Tonix Pharmaceuticals Holding's Income from Continuing Operations fell 101.02% to -$31.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$98.0 million, marking a year-over-year increase of 30.87%. This contributed to the annual value of -$136.7 million for FY2024, which is 39.20% down from last year.
- Per Tonix Pharmaceuticals Holding's latest filing, its Income from Continuing Operations stood at -$136.7 million for FY2024, which was down 39.20% from -$98.2 million recorded in FY2023.
- In the past 5 years, Tonix Pharmaceuticals Holding's Income from Continuing Operations registered a high of -$41.2 million during FY2020, and its lowest value of -$136.7 million during FY2024.
- In the last 3 years, Tonix Pharmaceuticals Holding's Income from Continuing Operations had a median value of -$98.2 million in 2023 and averaged -$107.8 million.
- Data for Tonix Pharmaceuticals Holding's Income from Continuing Operations shows a maximum YoY tumbled of 81.86% (in 2020) over the last 5 years.
- Tonix Pharmaceuticals Holding's Income from Continuing Operations (Yearly) stood at -$41.2 million in 2020, then tumbled by 79.05% to -$73.7 million in 2021, then decreased by 20.07% to -$88.5 million in 2022, then declined by 10.99% to -$98.2 million in 2023, then plummeted by 39.20% to -$136.7 million in 2024.